G2GBIO Inc., a clinical-stage biotech company, provides pharmaceutical products. The company’s pipeline products includes GB-5001, GB-5001A, and GB-5112 for the treatment of alzheimer’s disease; GB-6002, an opioid drug that is used for post-operative pain treatment; GB-7001 for type-2 diabetes treatments; GB-5313 for the treatment of Osteoarthritis; GB-7101 and GB-7103 for the treatment of prostate cancer; GB-6201 and GB-6203 for androgenetic alopecia treatments; and GH-001 for the treatment of Hepatitis B. It also develops GB-2001 for animal castration; and GB-2006, an animal postoperative pain relief drug, which is in clinical trial stage. The company was founded in 2017 and is headquartered in Cheongju-si, South Korea.
Metrics to compare | 456160 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship456160PeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −5.6x | −0.6x | |
PEG Ratio | 0.00 | −0.15 | 0.00 | |
Price/Book | 0.0x | 2.8x | 2.6x | |
Price / LTM Sales | 0.0x | 12.4x | 3.4x | |
Upside (Analyst Target) | 0.0% | 8.5% | 41.5% | |
Fair Value Upside | Unlock | 6.2% | 5.5% | Unlock |